Skip to main content
. 2019 Nov 4;10(11):837. doi: 10.1038/s41419-019-2063-6

Fig. 2. Yoda1 sensitizes cancer cells to TRAIL-mediated apoptosis.

Fig. 2

a Representative flow plots of Annexin-V assays of PC3 cells after treatments with combinations of 0.1% DMSO or 10 µM Yoda1 and 50 ng/mL TRAIL treatments. b Average cell viabilities of PC3 cells treated with DMSO or Yoda1 and TRAIL (n = 3). c TRAIL sensitization of PC3 cells by Yoda1 at 1, 4, 8, 12, and 24 h timepoints (n = 3). d TRAIL sensitization of PC3 cells by Yoda1 after siRNA knockdown of Piezo1 (n = 3). e TRAIL sensitization of PC3, DU145 (100 ng/mL), COLO 205 (10 ng/mL), and MDA-MB-231 (50 ng/mL) cells treated with 1, 5, 10, and 50 µM Yoda1 (n = 3). f PC3 cells treated with Yoda1 and TRAIL and the addition of calpeptin (n = 3). a One representative experiment of three independent experiments. b–f Means and SD of three independent experiments. Statistical analysis performed using one-tailed ANOVA (b, f) and two-tailed unpaired t-test (d). *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001